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ABSTRACT 
Targeting Sphingosine Kinase 2 as a Treatment for Cholangiocarcinoma 
 
By Anthony Dean Stillman 
 
A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science 
at Virginia Commonwealth University. 
Virginia Commonwealth University, 2019. 
Major Director: Huiping Zhou, Professor, Department of Microbiology and Immunology 
 
Cholangiocarcinoma (CCA) has a high mortality rate and its occurrence is rising. This increase 
prompts the need for improved CCA treatments. Studies have suggested that CCA is highly 
reliant on the sphingosine-1-phosphate-receptor-2 (S1PR2) and sphingosine kinase 2 (SphK2). 
Recently, a competitive SphK2 inhibitor, ABC294640, has been approved for clinical trial. 
ABC294640 has the potential to treat CCA, which is support by a phase I clinical study that was 
able to temporarily treat a patient suffering from metastasized CCA with ABC294640. To 
determine the viability of ABC294640 as a treatment for CCA, this study focused on 
determining the effects of ABC294640 on rat CCA cell lines. We found that ABC294640 
inhibited the growth and migration of CCA and CAFs cells. The growth and count of 3-D 
organotypic co-culture of  CCA and CAFs, which forms the “duct-like” structures, were reduced 
by ABC294640. The potential of inhibiting SphK2 as a treatment for CCA is supported by our 
finding of increased expression of S1PR2 and SphK2 in CCA patient liver samples. In 
conclusion, ABC294640 represents a potential therapeutic agent for CCA.
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Chapter 1: Introduction 
1.1 Cholangiocarcinoma and Risk Factors. 
Cholangiocarcinoma (CCA) is the second most common form of liver cancer, behind 
hepatocellular carcinoma (HCC). In the United States, China, and Thailand there are 1.67, 17.5, 
and 60 per 100,000 people annually diagnosed with CCA, respectively (Figure 1). The rate of 
intrahepatic CCA (iCCA) diagnosed has been gradually increasing due to the changes in global 
dietary habits, population chemical exposure, and other factors1. Patients that are diagnosed with 
early-stage CCA have a 30% chance of surviving 5-year past their diagnosis with treatment, 20% 
of CCA cases are diagnosed at early stages. Patients with the late-stage diagnosis have ~2% of 
surviving 5-year past diagnosis even with treatment2, 43.  The increasing global prevalence and 
the lack of effective treatment to combat the disease have created an urgent need for developing 
novel therapies for CCA.   
CCA is derived from the cholangiocytes that make up the lining of the bile duct and its 
branches1. The liver synthesizes bile to be stored in the gallbladder. The bile duct transports bile 
from the liver/gallbladder to the intestine3. Due to CCA heterogeneous nature, its severity can be 
defined by CCA location within the bile duct system. The bile duct has two branches that reside 
within the liver, CCA that is found within those branches or are within the liver is referred as 
intrahepatic CCA (iCCA). CCA found in the first-half of the bile duct trunk below the bile duct 
branches is perihilar CCA (pCCA). The second half of the bile duct trunk can contain distal CCA 
(dCCA). The relative occurrence and 5-year survival rate of iCCA, pCCA, and dCCA is 10% 
and ~32.5%, ~65% and ~26%, and ~25% and ~27% respectively (Figure 2)4. The diagnosis rate 
of iCCA has been increasing1. 
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Figure 1: Global Cholangiocarcinoma Incident Rate. Numbers are cholangiocarcinoma 
cases per 100,000 people per region. Intrahepatic (IH) and extrahepatic (EH) 
cholangiocarcinoma with arrows indicating tempral trends of incident and greater sign 
indicates which form is most prevalent. 
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Occurrence: 10% 
Survival: 25 - 40% 
Occurrence: 60 - 70% 
Survival: 11 - 41% 
Occurrence: 20 - 30% 
Survival: ~27% 
Figure 2: Classification of Cholangiocarcinoma. Types of cholangiocarcinoma 
(CCA) with associated relative occurrence and 5-year survival expectancy4.  
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The global diagnosis rate of CCA is gradually increasing1. This is due to improvement in 
diagnosis methods, an increase of individuals with established risk factors, and the emergence of 
new risk factors1. Until recently, CCA occurred in very specific parts of the world, namely north 
Thailand and southern China. The reason for the locality of the disease is due to the very specific 
environmental factor of fasciola hepatica (Liver Fluke), a parasite that infects and grows in 
human livers, causing liver fibrosis. Liver fibrosis increases the risk of developing CCA1. 
Many CCA risk factors induce liver fibrosis. Factors that induce liver fibrosis are primary 
sclerosing cholangitis, toxins (alcohol), liver cirrhosis, and HCV. Other risk factors are bile duct 
cysts, bile duct stone, inflammatory bowel disease (IBD), obesity, and diabetes (Figure 3)1,4. Out 
of these risk factors, obesity and diabetes have had the most significant global increase over 
recent times5,6, which can explain why CCA rates have been increasing outside of east Asia1.  
1.2 Cholangiocarcinoma Treatments. 
The current treatment for CCA is limited. Radiation, chemotherapy, and surgery each 
give patients a 20% chance of surviving 5-year past diagnosis9,10,11. The combination of these 
conventional treatments can increase a patient’s survival chances to 70%9. Treatments more 
specific for CCA involve surgically replacing portions of the liver and bile duct system. The 
most successful specific procedure for CCA is liver transplant increasing the patients' 5-year 
survival chances to 53%8. The effectiveness of this procedure is for two major reasons. The 
patient’s possibly cancer infiltrated liver being removed, also removing the metastasized cancer. 
And one of the major factors that promote the spread of CCA is a diseased liver, thus replacing 
the patient’s unhealthy liver with a healthy liver decreases the progression of CCA.  Liver 
transplants are rarer and far more effective then bypass procedures, which have a 5-year survival 
rate of ~0%12,13. These bypass procedures are invasive and are implemented in patients 
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Figure 3: Risk Factors. The established and possible risk factors that assist the progression of 
Cholangiocarcinoma (CCA). Risk factors are linked to liver disease
1,4
. 
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with late-stage CCA, thus these procedures only extend patient survival slightly. The biliary 
bypass is removing the bile duct and replacing it with a portion of the gut12. Stent placement is 
replacing the bile duct with a polymer tube13. The reason for the effectiveness of bypasses is it 
removes the source of CCA, the bile duct, and stopping bile acids from reaching CCA and 
cholangiocyte cells (Figure 4).  
The rise of CCA occurrence and CCA risk factors has prompted a response by the 
medical community, which has increase diagnosis methods of CCA. The ability to diagnosis 
CCA has been improved by the addition of endoscopic ultrasound and blood tests for liver 
function and tumor antigens7. Even with these additional tools, few CCA cases are caught at 
early stages when treatment is the most effective7. For the sake of global health, new novel 
medicines to treat late-stage CCA need to be developed. 
1.3 Bile Acids. 
Bile acids are a class of zwitterionic ligands/detergent produced in the liver14. Bile acids 
are stored in the gallbladder and transported down the bile duct and through the gut to act as 
detergents to help to solubilize the lipids and absorb nutrition 15. Once the bile acids have 
reached the ileal, enterohepatic circulation transports 95% of the bile acids back to the liver to be 
reused, via the portal venous system18. While on this journey, bile acids can be conjugated into 
conjugated bile acids (CBA) in the liver and deconjugated by bacteria in the colon. Glycocholic 
acid (GCA) and taurocholic acid (TCA) are the two major primary bile acids. These CBAs 
endocrinologically affect different types of cells throughout the liver and gut axis (Figure 5)15. 
The cholangiocytes and myofibroblasts that make up the bile duct possess cell surface receptors 
7 
 
that can be activated by CBA. The cellular response is based on the ratio of CBA and their target 
receptors the cell possesses19,20. The most prevalent CBA receptor are sphingosine-1-phosphate  
 
 
 
 
 
 
Figure 4: Treatments of Cholangiocarcinoma. Various types of treatments for 
cholangiocarcinoma (CCA) and the associated 5-year survival rate after diagnosis with 
treatment.
 9,8,10,11,12
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Figure 5: Bile-Acid synthesis and Intrahepatic Transport. A) Bile acid synthesis and 
conjugation that occurs in the liver. B) Intrahepatic circulation that transports the bile acids down 
the bile duct/gut followed by transport of bile acid through the ileum into the portal venous system. 
The portal venous system transports 95% of the bile acids to the liver for reuse
38,37
. 
A) B) 
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receptor 2 (S1PR2)19. This receptor is critical in CBA-induced CCA cell metabolism, 
proliferation, and migration. 
1.4 S1PRs and Sphingosine Kinase 2 (SphK2) Pathway. 
There are five sphingosine-1-phosphate receptors (S1PR1-5) and their expression varies 
on cell types. S1PRs have many downstream targets, making it difficult to target these receptors 
as a treatment without unwanted side effects21. The most prevalent of these receptors in the 
liver/bile duct is S1PR222. Both cholangiocytes and the myofibroblasts of the bile duct possess 
S1PR2 on their cell surface19,20. S1PR2 are G-protein-coupled receptors (GPCRs)22. GPCRs are a 
large family of transmembrane receptors. GPCR is composed of an extracellular surface ligand-
binding domain and an intracellular guanine nucleotide exchange factor (GEF); which is also 
composed of a complex of α, β, and γ subunits24. When a CBA or S1P binds to S1PR2, it induces 
a conformation change that activates the GEF. The activated GEF supplants the GDP on the α-
subunit with a GTP, allowing it to disassociate from the β and γ subunits. The disassociated 
subunits induce a reaction across the cell surface-associated proteins leading to the activation of 
the epidermal growth factor receptor (EGFR)24. EGFR activates the MAPK/ERK pathway, 
causing the phosphorylation of ERK1/2 into p-ERK1/2. The p-ERK1/2 is transported to the 
nucleus where it phosphorylates SphK2 at ser-351 into p-SphK225.  Activated SphK2 generates 
nuclear S1P, which is a powerful inhibitor of HDAC1/226. The inhibition of HDAC1/2 by S1P 
leads to increasing histone acetylation causing epigenetic changes and altering gene expression 
(Figure 6)27,42. The activation of S1PR2 in CCA drives the progression of cancer via SphK2 and  
10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: S1PR2/ERK/SphK2 Pathway. Conjugated bile-acid (CBA) activates 
sphingosine-1-phophate receptor 2 (S1PR2). S1PR2 G-protein-coupled complex 
releases the alpha-subunit (α1) which activates phospholipase C-beta (PLCβ) and 
Src kinase. This leads to the activation of matrix metallopeptidase, which partially 
degrades Pro-EGFR ligand. The ligand binds epidermal growth factor receptor 
(EGFR) allowing it to assist S1PR2 activate extracellular signal-regulated kinases 
1/2 (ERK1/2). ERK1/2 enters the nucleus and phosphorylates sphingosine kinase 2 
(SphK2). SphK2 phosphorylates sphingosine (Sph) into sphingosine-1-phosphate 
(S1P). S1P inhibits HDAC1/2 increasing histone acetylation thus altering gene 
expression42.  
 
11 
 
other pathways27,28. These pathways increase cell growth, proliferation, and metabolism27. The 
most impactful and enduring effect is the epigenetic alterations incurred by SphK2. Increase 
activity of SphK2 has been linked to increases in neoplastic transformation, tumorigenesis, 
migration, proliferation, metastasis, metabolism, drug resistance, and overall cancer 
progression27, 44 - 46. The effect of SphK2 on cell proliferation is not limited to CCA cells, it also 
affects the cancer-associated myofibroblasts (CAFs) that support CCA may use the 
S1PR2/ERK/SphK2 pathway to progress the tumor microenvironment.  
Tumor cells can recruit surrounding cells for support. A major group that supports CCA 
tumors are CAFs. CCA cells release various ligands to recruit CAFs for assistance. CAFs 
perform activities that are crucial for the survival, progression, and metastasis of the CCA 
tumor41,29. Especially α-SMA positive CAFs, which have a positive correlation with tumor size 
and negative correlation with patient survival41. The CAFs promote the tumor via altering the 
tumor microenvironment and promoting the cancer cell growth directly, essentially assisting the 
CCA to achieve the various hallmarks of cancer. To induce angiogenesis, the CAFs release 
cytokines that attract macrophages to assist in angiogenesis. The CAFs surround the cancer cells, 
sheltering the tumor from an immune response. CAFs promote CCA growth by releasing growth 
factors and directly interacting with the CCA cells. Once the tumor is large enough, the CAFs 
release proteins that break down the extracellular matrix around the tumor, releasing the CAFs 
and the contained CCA cells away from the surrounding tissue leading to metastasis. The 
cooperation of the CAF cells with the CCA tumor is necessary for the progression of the 
cancer30. 
CCA cells communicate with the CAFs via various signaling pathways. CCA cells 
excrete S1P at a heightened rate compared to healthy cholangiocytes31. This unusual high levels 
12 
 
of S1P in the tumor microenvironment is known to promote CCA cell growth and most likely 
induces cancer-promoting behavior from CAFs29. This is supported by the presence of S1PR2 in 
CAF cells20. The presence of S1PR2 in the CAFs also allows for CAFs to be promoted by CBA 
that pass through the bile duct. This sensitivity to CBA is particularly crucial due to CCA and 
CAFs tumor masses blocking the bile duct, causing a backup and buildup of CBA around the 
tumor32. The backup increases the concentration of CBA around the tumor, promoting tumor 
growth via the S1PR2/ERK/SphK2 pathway32. S1PR2/ERK/SphK2 pathways importance to 
CCA/CAFs tumor growth, communication, and metastasis makes it a prime target for cancer 
treatment (Figure 7). Due to S1PR2 and ERK importance to other pathways, targeting them 
would have off-target effects. SphK2 is at the end of the pathway, making it a prime target for 
treatment.  
SphK2 is an enzyme that binds and phosphorylates sphingosine into S1P. SphK2 kinase 
function is primarily performed in the nucleus, as discussed before26. SphK2 has a sister protein 
that resides in the cytoplasm, SphK1. The SphK1/2 sister enzymes have very similar structures at 
their kinase active sites with the main difference between the sisters being in the length and 
composition of their c-terminuses, which determines the kinases locality within the cell. When 
activated, SphK1 binds to the interior of the cell membrane to produce S1P33. When SphK2 is 
inhibited, the activity and quantity of SphK1 are upregulated within the cell to seemingly 
maintain healthy extracellular and cytoplasmic S1P levels34. This is crucial due to the overall 
importance of S1P in the cytoplasm and blood/lymph for the normal function of the body. Thus,  
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Figure 7: Cancer-Associate Myofibroblasts of Cholangiocarcinoma. Cancer-
associated myofibroblasts (CAFs), cholangiocarcinoma (CCA), and other cells types 
endocrine communication, modifying the cancer microenvironment
39
. 
14 
 
inhibiting SphK2 will only lead to a decrease of S1P in the nucleus and not the rest of the body. 
SphK1 compensation of S1P while SphK2 is inhibited further limits the possible side effects of 
inhibiting SphK2, increasing SphK2 lure as a target for CCA treatment. There are several SphK2  
inhibitors available. 
1.5 SphK2 inhibitors.  
Extensive efforts have been made to develop specific SphK2 inhibitors. Most of the 
inhibitors bind both SphK1 and 2, due to the similar structures35. Recently isotype-specific 
inhibitors have been developed. The most promising of these compounds is ABC294640, which 
is a competitive inhibitor (Figure 8). ABC294640 has already been approved for the clinical 
trial. ABC294640 treatment can be taken orally in 250 mg dosage (~ 7 µM) with limited side 
effects36. A phase I study on a group of patients with various forms of cancer was conducted with 
ABC294640. Out of the various types of cancers, the patient with metastatic CCA had the most 
positive outcome47. The mechanism of how ABC294640 affects CCA is still being explored. 
Recently, a human intrahepatic CCA cell study was conducted to determine the mechanism 
ABC294640 inhibited CCA. The study showed that ABC294640 stopped SphK2 inhibition of 
NOXA production. NOXA inhibits MCL1, an anti-apoptotic protein that is a part of the BCL2 
family, thus increasing cell apoptosis. The study concluded ABC294640 indirectly induced 
apoptosis through the promotion of NOXA production. The study also showed that BCL2 family 
inhibitors synergized with ABC294640 to increase CCA apoptosis48. The study results are 
promising but did not include a healthy control cell line and their 50 µM ABC294640 dosage is 
far above the clinical standard. Further research needs to be done to better understand how 
ABC294640 effects CCA. A more potent sphK2 inhibitor is K145 hydrochloride (K145). K145    
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Figure 8: ABC294640 Mechanism on Sphingosine Kinase 2. ABC294640 is a 
competitive inhibitor for sphingosine kinase 2 (SphK2).  ABC294640 binds the 
phosphorylation site of SphK2, blocking sphingosine (Sph) from entering the site, thus 
halting the creation of sphingosine-1-phosphate (S1P)48.  
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has not been approved for clinical use and has the same competitive inhibitor traits as 
ABC294640, but is more toxic to cells51. 
1.6 Nanoparticle Drug Delivery. 
ABC294640 hydrophobic structure impedes its transport through the body, which can be 
circumvented by Nanoparticle drug delivery. Nanoparticles are micelle like structures made of 
various smaller artificial constructs41. This artificial construction makes the nanoparticles highly 
customizable; the customizable traits are as follows41. Nanoparticles are generally 100 to 500 nm 
in diameter; the size of a nanoparticle structure dictates its ability to pass through a cell 
membrane41. The interior of the nanoparticle can be modified to be able to seat specific particles 
for transport41. The exterior of a nanoparticle can possess antibodies or other structures that help 
guide the particle to cancer. Once the nanoparticle is inside the cell, it can gradually or 
immediately release its content inside the cell (Figure 9) 41. The nanoparticle can be designed to 
contain one or multiple drugs41. All these traits make nanoparticles a great partner for 
ABC294640 delivery.   
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Figure 9: Nanoparticle Drug Delivery. Drugs encapsulated in nanoparticle micelle constructs for 
transport into the cell and drug release.      
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Chapter 2: Materials and Methods 
2.1 Materials. 
• Trypsin-EDTA, (Gibco, ThermoFisher, 25200056 ) 
• Dulbecco’s Modified Eagle Medium (DMEM), (Gibco, 11995-065) 
• Fetal Bovine Serum (FBS), (Sigma, F2442) 
• Penicillin Streptomycin (P/S), (ThermoFisher, 15140122) 
• Phosphate Buffer Solution (PBS), (Sigma-Aldrich, P5494) 
• Insulin, 100 units per 100Ml 
• Dimethyl Sulfoxide (DMSO), (Sigma-Aldrich, D2650) 
• Trypan Blue, (Sigma-Aldrich, T8154) 
• Ammonium Persulfate, (Sigma-Aldrich, A3678) 
• 30% Acrylamide/Bis Solution 29:1, (BIO-RAD, 1610156) 
• TEMED (BIO-RAD, 161-0800) 
• SDS, (sodium dodecyl sulfate, L4509) 
• HEPES, (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, Sigma-Aldrich, H-9136) 
• KCl, (potassium chloride, Sigma-Aldrich, P-3900) 
• EDTA, (Ethylenediaminetetraacetic acid, Sigma-Aldrich, ED4S) 
• EGTA, (Ethylene glycol-bis(2-aminoethlether)-N,N,N',N'-tetraacetic acid Sigma-Aldrich, 
E0396) 
• NaF, (Sodium Fluoride, Sigma-Aldrich, S-1594) 
19 
 
• Na3VO4, (Sodium orthovanadate, Sigma-Aldrich, S6508) 
• Leupeptin, (Sigma-Aldrich, 103476-89-7) 
• Aprotinin, (Sigma-Aldrich, 9087-70-1) 
• Pepstatin A, (Sigma-Aldrich, 26305-03-3) 
• PMSF, (Phenylmethanesulfonyl Fluoride, Sigma-Aldrich, P7626) 
• NaCl, (sodium chloride, ThermoFisher, S641-212) 
• TergitolTM Solution (NP-40), (Sigma-Aldrich, 1002526600) 
• β-Glycerol phosphate, (Sigma-Aldrich, G-6251) 
• Glycerol, (Sigma-Aldrich, 56-81-5) 
• Benzamidine, (Sigma-Aldrich, 206752-36-5) 
• BIO-RAD Protein Assay Dye Reagent Concentrate, (BIO-RAD, 5000006) 
• Precision Plus ProteinTM Dual Color Standards, (BIO-RAD, 161-0374) 
• Nitrocellulose Membrane Roll, (GVS North America Sanford, 1215471) 
• Tris base, (Trizma Hydrochloride, Sigma-Aldrich, T3253) 
• Glycine, (Sigma-Aldrich, G-8898) 
• Methanol, (Fisher, A454-4) 
• Dry-Milk 
• BSA, (Bovine Serum Albumin, Sigma, B4287) 
• Tween®-20, (Sigma-Aldrich, 9005-64-5) 
• ECL, (PerkinElmer, ORT2655) 
• TRIzol, (TRI-Reagent®, Sigma-Aldrich, T9424) 
• Chloroform, (Sigma-Aldrich, 67-66-3) 
• 2-propanol, (Sigma-Aldrich, I9516) 
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• Ethanol, (Koptec, 64-17-5) 
• High-Capacity cDNA Reverse Transcription Kit, (ThermoFisher, 4368814) 
• iQTM SYBR Green Supermix reagents 
• Formaldehyde, (Sigma-Aldrich, 252549) 
• Collagen I, Rat Tail, (Corning®, 354236) 
• NaOH, (Sodium hydroxide, Sigma-Aldrich, 7647-14-5) 
• Xylenes, (Histoprep, 1330-20-7) 
• Hydrogen peroxide, (Sigma-Aldrich, 216763) 
• Na2HPO4, (Sodium phosphate dibasic, Sigma-Aldrich, 7558-79-4) 
• KH2PO4, (Potassium phosphate monobasic, Sigma-Aldrich, 7778-77-0) 
• H&E staining kit, (Hematoxylin and Eosin, Abcam, ab245880) 
• VECTASTAIN® ABC HRP Kit (Peroxidase, Rat IgG, VectorLab, PK-4004) 
• DAB Peroxidase (HRP) Substrate Kit (with Nickel), 3,3’-diaminobenzidine (VectorLab, 
SK-4100) 
• VECTASHIELD® Hardset™ Antifade Mounting Medium with DAPI (VectorLab, 
H1500) 
• CCK-8, (Cell-Counting Kit-8, Dojndo, CK04) 
• ABC, (ABC294640, Selleckchem, S7174) 
• TCA, (Sodium Taurocholate Hydrate, Sigma-Aldrich, 345909) 
• TritonTM 100 (Sigma-Aldrich, T9284) 
2.2 Solutions and Buffers. 
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2.2.1 Buffer A: 10 mM, 7.4 pH, HEPES, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 2 mM 
NaF, 2 mM, 25 µg/mL leupeptin, 25 µg/mL aprotinin, 10 µg/mL pepstatin A6305-03-3), and 0.1 
mM PMSF. 
2.2.2 Buffer B: 20 mM, 7.4 pH, HEPES, 0.4 M NaCl, 1.0 mM EDTA, 1.0 mM EGTA, 2mM 
NaF, 2 Mm Na3VO4, 25 µg/mL leupeptin, 25 µg/mL aprotinin, 10 µg/mL pepstatin A, and 0.1 
mM PMSF. 
2.2.3 Total: 25 mM, 7.4 pH, β-Glycerol phosphate, 5 mM EDTA, 5 mM EGTA, 25 mM NaF, 
1mM Na3VO4, 1.0% triton X-100, 0.1.0% SDS, 10% glycerol, and 5 mM benzamidine.  
2.2.4 AP:1.0 g ammonium persulfate dissolved in 10 mL of ddH2O. 
2.2.5 SDS: 10 g Sodium dodecyl sulfate dissolved in 100 mL of ddH2O. 
2.2.6 Running Buffer x5: 125 mM Tris base, 2.5 M Glycine, SDS 5 g/mL. pH 7.4. 
2.2.7 Running Buffer: 200 mL of running buffer x5 and 800 mL of ddH2O. 
2.2.8 Transfer Buffer x10: 1.92 M glycine and 250 mM tris base. pH 7.4. 
2.2.9 Transfer Buffer: 100 mL of transfer buffer x10, 700 mL of ddH2O, and 200 mL of 
Methanol.    
2.2.10 TBS x10: 100 mM Tris base and 1.5 M NaCl. pH 7.4. 
2.2.11 TBST: 100 mL of TBS x10, 900 mL of ddH2O, and 1 mL tween
®-20. 
2.2.12 1 mM EDTA: 372 mg of EDTA dissolved in 1 mL of ddH2O. pH 8.0. 
2.2.13 PBS x10: 80 g of NaCl, 2.0 g of KCl, 14.4 g of Na2HPO4, and 2.4 g of KH2PO4 
dissolved in 1.0 L. pH 7.5.  
2.2.14 PBST: 100 mL of PBS x10, 900 mL of ddH2O, 1 mL of tween
®-20. 
2.2.15 2.5% BSA-PBS: 0.2% triton X-100 and 2.5% BSA in PBS buffer. 
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2.3 Cell Culture.  
2.3.1 Cell lines: Five ratcell lines were used for the various experiments in this study. BDE1 
cells are a immortalized non-tumorigenic cell line that represents the normal bile duct 
cholangiocytes cells. The following cell lines were BDEsp tumor-derived. BDEsp-TDFE4 cancer-
associated myofibroblasts (CAFs) cell line (clone E4) and BDEsp-TDEH10 cholangiocarcinoma 
(CCA) cell line (clone H10). These two cell lines were extracted from the same tumor and 
cooperate with each other. A more aggressive forms of BDEsp-TDE cell line are BDEsp-TDEneu 
and BDEsp-TDEc. BDEsp-TDEneu cells have a mutation in the HER2 gene, increasing the 
receptors expression and BDEsp-TDEc is the same cell line, without the mutation.  
2.3.2 Cell Medium: 450 mL of DMEM GIBCO medium, 50 mL of fetal bovine serum (FBS), 5 
mL of penicillin-streptomycin, 3.48 mg of transferrin, and 97 µL of insulin were mixed. The 
solution was filtered and added to 500 mL of DMEM GIBCO medium to create 10% FBS 
medium. 01% FBS medium contains 10 mL of FBS and instead of 50 mL of FBS. The medium 
was stored at 4 °C and warmed in 37 °C water bath before use. 
2.3.3 Cell Culture: All BDEsp cell lines were cultured in 10 mL of DMEM GIBCO medium 
with 10% FBS, 1% penicillin-streptomycin, 1 µmol/L of insulin, and 5 µg/mL of transferrin. The 
cells were incubated at 37 °C and 5.0% CO2 in a humidified cell culture incubator.  
2.3.4 Cell Sub culturing: Cells were allowed to incubate and divided in 100 mm plate until 
reaching 70% to 90% confluency, 3 to 4 days. In cell-hood, the medium was removed from the 
plate and 3 mL of trypsin was added. The plate was placed in the 37 °C cell incubator for 3 to 5 
minutes. Detached cells were washed off plate with trypsin and added to warm medium equal to 
trypsin in volume, to deactivate the trypsin. The medium was centrifuge for 5 minutes at 1350 
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rpm. The medium was aspirated from cell pellet. Cells were suspended in fresh warm medium 
and added to 100 mm cell plates containing 10 mL of warm DMEM medium. The cells were 
incubated at 37 °C and 5.0% CO2 in humidified cell culture incubator.   
2.3.5 Freezing: 1.0*106 Cells were suspended in 20% FBS, 10% DMSO, and 70% cell medium 
to a final volume of 1.5 mL. The solution was added to cryotube and placed in -80 °C storage for 
3 to 5 days. Then the cells were transferred to liquid nitrogen tanks for long term storage. 
2.3.6 Thawing: Frozen cells were kept in cryotube and stored in liquid nitrogen. Once removed 
from liquid nitrogen, cryotube containing cells are incubated in 37 °C water bath for one minute, 
to thaw cells. The cryotube was taken into cell-hood and cell solution was transferred into 3 mL 
of warm medium. The medium was centrifuge for 5 minutes at 1350 rpm. In the cell-hood, 
medium was removed from the cell pellet. Cells were suspended in fresh warm medium and 
added to 100 mm cell plates containing 10 mL of warm medium. Cells were incubated overnight 
at 37 °C. After overnight incubation, the medium was refreshed and the incubation of the cells 
resumed. 
2.4 Western Blot Analysis. 
2.4.1 Cytosol and Nucleoplasm Protein Lysate Extraction: Cells in a 60 mm plate at 80% to 
90% confluency were washed with 6 mL of cold PBS 3 times. 400 µL of buffer A was added to 
plate to cover cells. Cells were scraped off the plate and pipette into 1.5 mL tube. The solution 
was vortexed for 10 seconds and incubated for 15 minutes on ice. 25 µl of 10 % NP-40 is added 
to solution and vortex for 10 seconds, then incubate on ice for 30 minutes. In 4 °C, centrifuge for 
1 minute at max speed. Collect cytosol supernatants from nucleus pellet. Resuspend the nuclear 
fraction in 30 µl of buffer B with pipette. Vigorously shake the tubes for 20 minutes at 4 °C on 
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shaking platform. Spin at 4,000 rpm at 4 °C for 5 minutes. Transfer the nuclear fractions to clear 
tubes. Measure protein concertation and store at -80 °C. 
2.4.2 Cell Total Protein Lysate Extraction: Cells in a 60 mm plate at 80% to 90% confluency 
were washed with 6 mL of cold PBS, pH 7.4, 3 times. 200 µl of total protein lysis buffer was 
added to cover cells. Cells were scraped off the plate and pipette into 1.5 mL tube and vortexed 
for 10 seconds. Freeze cells at -80 °C for 2 hours. Thaw solutions on ice and centrifuge at 12,000 
rpm for 10 minutes. Collect lysate and transfer to final tube. Measure protein concentration and 
store at -80 °C. 
2.4.3 Tissue Total Protein Lysate Extraction: Add 50 mg of tissue into 1 mL of total protein 
lysis buffer. Homogenize Tissue with Precellys Evolution Homogenizer, Bertin Technologies 
(P000062-PEV00-A). Freeze cells at -80 °C for 2 hours. Centrifuge samples at 12,000 rpm for 
10 minutes. Collect lysate and transfer to the final tube. Measure protein concentration and store 
at -80 °C. 
2.4.4 Measuring Protein Concentration: Mix assay solution of 1-part Protein Assay Dye and 
4-parts deionized water. Aliquot assay solution into 500 µL fractions in 1.5 mL tube. Pipette 1.0 
µL of protein solution into assay solution fraction and mix. Pipette 200 µL of the mixture into 2 
wells of 96-well plate. Pipette 200 µL of assay solution into 2 wells of 96-well plate; this will act 
as a negative control. Measure wells absorbance at 600 nm. Calculate protein concentration.   
2.4.5 Protein Gel Electrophoresis: A fraction of protein solution containing a sum of 35 µg of 
protein was add to a 1.5 mL tube. The fraction was then diluted with ddH2O and 10 µL XT 
sample buffer x4 to a final volume of 40 µL. The mixture was then incubated in heating block at 
100 °C for 15 minutes to denature the protein. Denatured samples were incubated on ice or 
stored at -20 °C until gel is prepared. Protein gels were fixed to western electrode chamber and 
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placed in electrophoresis tank. Chambers and tank were filled with running buffer solution. 
Precision Plus ProteinTM Dual Color Standard is added to book-ending wells of the gel. 
Denatured protein fractions were pipetted into wells. Electrophoresis was started at 80 V for 15 
minutes and the rest of the run was done at 120 V. Run was complete when ladder reached the 
bottom of the gel.   
2.4.6 Gel to Membrane Protein Transfer: Protein was transferred from gel to nitrocellulose 
membrane using a wet transfer method. Gel and membrane were sandwiched together in a 
cassette with foam pad and filter paper. Cassette was placed in buffer tank and tank was filled 
with transfer buffer. Protein was then transferred from gel to membrane with 0.32 W current for 
80 minutes while kept cold.  
2.4.7 Membrane Blocking: Once the protein has been transferred, the nitrocellulose membrane 
was placed in container filled with TBST. 5.0% milk blocking solution was created by mixing 
5.0 g of dry milk into 100 mL of TBST. The TBST was poured off the membrane and blocking 
solution was added. Blocking was done for 2 hours at room temperature (RT) on rocker.  
2.4.8 Primary Antibody Incubation: 1.0% BSA solution is composed of 1.0 g of bovine serum 
albumin (BSA) in 100 mL of PBST buffer. Primary antibody solution is 1:1000 or 1:500 
antibody dilution in 1.0% BSA solution. Membranes were submerged in primary antibody 
solution and incubated overnight on a rocker at 8 °C. After incubation, membranes were washed 
with TBST three times at room temperature (RT) on rocker for 15 minutes each.  
2.4.9 Secondary Antibody Incubation: 1.0% BSA solution is composed of 1.0 g of bovine 
serum albumin (BSA) in 100 mL of TBST buffer. Secondary antibody solution is 1:1000 
antibody dilution in 1.0% BSA solution. Membranes were submerged in secondary antibody 
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solution and incubated for 1 hour on a rocker at RT. After incubation, membranes were washed 
with TBST three times at room temperature rocker for 15 minutes each.  
2.4.10 Imaging proteins: After residual secondary antibody is washed off, the membranes were 
imaged. Membranes were dried and placed in Bio-Rad Gel Doc XR+ Imaging System. Enhanced 
luminol-based chemiluminescent (ECL) was added to the surface of the protein and images were 
taken with optimal system settings.       
2.5 3-D Organotypic Culture Model of Cholangiocarcinoma. 
2.5.1 3-D Organotypic BDEsp-TDFE4 and BDEsp-TDEH10 Tumor Culturing: The following 
procedure has been previous described41 and was done under a cell-hood. The following mixture 
is for twelve 1.0 mL Organotypic disks. 11.2x106 of BDEsp-TDEH10 and 5.6x10
6 of BDEsp-
TDFE4 cells were diluted into 9.845 mL of 10% DMEM medium. 3.655 mL of filtered Corning® 
Collagen I, Rat Tail was added to the medium and mixed with a pipette. To induce the 
solidification of the mixture, 84.1 µL of filtered 1.0 N NaOH solution was added and followed 
by mixing with a pipette. 1.0 mL of solution was added to each well of a 12-well cell culture 
plate. The culture was then placed in the cell incubator for 1 to 2 hours, allowing the disk to 
solidify. Once solidified, the disks were transferred to two 6-well cell culture plates with 3 mL of 
warm medium. The organotypic culture was placed back into the cell incubator.  
2.5.2 3-D Organotypic Treatment, Fixing and embedding: Following was done under a cell-
hood. The treatment began the day after organotypic formation. The medium was refreshed 
before treatment was added. Treatment was refreshed every other day for eight days. After 
treatment, the organotypic cultures were washed with formaldehyde (37% wt diluted in ddH2O) 
and then incubated in 5.0 mL of formaldehyde (37% wt diluted in ddH2O) at 8 °C overnight. 
Samples were then delivered to a histology lab for embedding and sectioning.   
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2.6 Immunohistochemistry. 
2.6.1 Paraffin removal, Antigen Unmasking, Blocking: Paraffin-embedded tissue sections on 
slides are heated at 60 °C for 5 to 10 minutes. The slides are then placed in a cassette and 
undergo a serious of washes to remove the paraffin and rehydrate the samples. The serious is 
three 100% xylene submersions for 15 minutes, three 100% ethanol submersions for 10 minutes, 
75% ethanol submersions for 5 minutes, 50% ethanol submersions for 5 minutes, 25% ethanol 
submersions for 5 minutes, and a final wash with ddH2O for 5 minutes. For antigen unmasking, 
slides were placed in holder filled with 1 mM EDTA buffer pH 8.0 and sub-boiled for 35 
minutes. The container and slides were cooled in ice water for 20 minutes. Slides were washed 
for 5 minutes in ddH2O.  To block endogenous peroxidase activity, slides were incubated at RT 
in 3.0% hydrogen peroxide diluted in methanol for 30 minutes. After blocking, slides are washed 
with PBST three times for 5 minutes each. Samples were blocked for 1 hour with 0.2% Triton X 
100 and 2.5% BSA-PBS blocking solution at RT. This preparation was followed by staining and 
immunohistochemistry.  
2.6.2 Hematoxylin and Eosin: Paraffin removal, antigen unmasking, blocking of samples are 
described above. Staining was conducted with ABCAM H&E Staining Kit (ab245880). Slides 
were incubated in hematoxylin for 10 minutes at RT and in the dark. The excess staining was 
rinsed off with ddH2O for 5 minutes. Excess ddH2O was removed and slides were incubated in 
Bluing reagent (0.2% Ammonia Water Solution) for 5 minutes at RT. The excess staining was 
rinsed off with ddH2O for 5 minutes. Slides were incubated in eosin for 15 minutes at RT. The 
excess staining was rinsed off with ddH2O for 5 minutes. Slides were then washed briefly in 75% 
ethanol. Samples were then dehydrated with the following serious of washes. Three 100% 
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ethanol submersions for 10 minutes and three 100% xylene submersions for 15 minutes. Slides 
were placed flat in a hood for 1 minute to allow air drying. Permount was add on top of the 
samples and cover slide adhered. The slides were kept in the hood overnight to allow permount 
to solidify. Stained samples were then sent to MCV Clinical Support Center to be diagnosed.  
2.6.3 TROMA-III (CK-19) Staining: Paraffin removal, antigen unmasking, blocking of 
samples are described above. TROMA-III (CK-19) antibody was purchased from Developmental 
Studies Hybridoma Bank (DSHB). Samples were incubated in 1:100 TROMA-II antibody 
diluted in triton X-100 and 2.5% BSA-PBS blocking solution overnight at 8 °C. The primary 
antibody was then washed off with PBST three times for 5 minutes each. Incubation of 
secondary antibody and staining was conduct as instructed in rat specific VECTASTAIN® ABC 
HRP Kit and DAB Peroxidase (HRP) Substrate Kit (with Nickel), 3,3’-diaminobenzidine. 
Samples are stained with hematoxylin for 20 seconds and rinsed off with ddH2O for 5 minutes. 
Samples were then dehydrated with the following serious of washes. Three 100% ethanol 
submersions for 10 minutes each and three 100% xylene submersions for 15 minutes each. Slides 
were placed flat in a hood for 1 minute to allow air drying. The slides were kept in the hood 
overnight to allow permount to solidify. The slides were kept in the hood overnight to allow 
permount to solidify.  
2.6.4 Immunofluorescence: Paraffin removal, antigen unmasking, blocking of samples are 
described above. Samples were incubated in 1:20 primary antibody diluted in triton X-100 and 
2.5% BSA-PBS blocking solution overnight at 8 °C. The primary antibody was then washed off 
with PBST four times for 5 minutes each. Samples were incubated in 1:1,000 secondary antibody 
diluted in triton X-100 and 2.5% BSA-PBS blocking solution for 1 hour at RT. The secondary 
antibody was then washed off with PBST four times for 5 minutes each. Excess buffer was 
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removed and cover slips were mounted on the slides with VECTASHIELD® Hardset™ Antifade 
Mounting Medium with DAPI (H1500, Vector). Slides were then imaged with confocal 
fluorescence microscopy running on ZEISS imaging program.  
2.7 CCK-8 Viability Rate. 
2.7.1 Treatment and CCK-8 Viability Rate: 4,000 cells were added to each well of a 96-well 
plate in 100 µL of 1.0% FBS, warm DMEM medium and placed in cell incubator overnight. 100 
µL of fresh 1% FBS, warm DMEM medium containing x2 treatment concentration was added to 
each well. The plates were placed in the cell incubator for 48 hours. After incubation, an initial 
reading of 450 nm absorbance was conducted on the wells. Three of the wells in the plates were 
treated with 10 µL of 1% triton X-100 to act as negative controls. 10 µL of CCK-8 (Cell 
Counting Kit-8, Dojindo Laboratories, CK09) was added to each well. Reading of 450 nm 
absorbance was conducted between 2 and 4 hours after CCK-8 was added. The survival rate was 
then calculated with the initial and final readings. The plates had their initial readings taken at 
450 nm to provide a background reading. To create a negative control, in each plate two wells 
were treated with 10 µL of 10% triton X-100 and incubated for 15 minutes to allow all the cells 
in those well to undergo apoptosis. The cell counting was conducted with a CCK-8 kit. 10 µL of 
CCK-8 solution was added to each well and allow to incubate for 2 to 4 hours. Throughout this 
time, the plate was periodically read at 450 nm until a few of the readings had a value between 
0.9 and 1.0. The final reading was subtracted by initial reading to remove the background for 
each well, followed by the negative controls value being subtracted from the background free 
final reading to remove the absorbance caused by the natural decay of CCK-8, this would result 
in the final value (final value = (final reading – initial reading) - (Negative control – initial 
reading)). 
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2.8 Migration Assay. 
2.8.1 Migration Assay: For cell confluency to fall between 70% to 80% confluency in 6-well 
plates, 0.7x106 BDEsp-TDFE4 were added to each well in 3 mL of DMEM medium. The cells 
were placed overnight in cell incubator to allow them to adhere to the plate. A gap was made 
down the middle of the bed of cells in each well with a 20 µL pipette tip and the medium was 
refreshed with 1.0% FBS, warm DMEM medium to remove floating cells. Initial imaging of the 
gap was taken, three images per well. The wells were then treated. Imaging of the same location 
was done at 24 and 38 hours. The migration rate was then measured with ImageJ. 
2.9 Statistics. 
Each experiment was repeated at least 3 times (n ≥ 3). The results are represented as means with 
SD or SEM error bars. The analysis was performed on GraphPad Prism 8.0 (GraphPad Soft Inc., 
San Diego, CA).  The one-way analysis of variance (ANOVA) and student t-test were used to 
analyze data and determine statistical significance. Significant P-values were set to *P < 0.05, 
**P < 0.01, ***P < 0.001, and ****P < 0.0001. 
 
 
 
 
 
 
 
31 
 
2.10 Antibodies. 
Target Protein Molecular Weight Species Manufacturer CAT# 
SphK1 48 kDa Rabbit Santa Cruz SC-48825 
SphK2 69 kDa Rabbit ProteinTech 17096-1-AP 
S1PR2 50 kDa Mouse ProteinTech 21180-1-AP 
ERK1/2 44/42 kDa Rabbit Santa Cruz SC-154 
p-ERK1/2 44/42 kDa Mouse Santa Cruz SC-7383 
Actin 42 kDa Mouse DSHB  JLA20 
H4K5ac 11 kDa Rabbit EpiGentek A-4027-050 
H3K9ac 17 kDa Rabbit EpiGentek A-4022-025 
H2BK12ac 15 kDa Rabbit EpiGentek A-68352-050 
Histone H3 18 kDa Rabbit EpiGentek A-1112-100 
 
Target Species Species Function Manufacturer CAT# 
Rabbit Goat IM Bio-Rad 170-6515 
Mouse Goat IM Bio-Rad 170-6516 
Rabbit Goat IF Complete A21206 
Rabbit Goat IH Vector Laboratories BA-4000 
 
 
Table 1: Antibodies. A) Antibodies for immunoblotting, target, expected weight, antibody’s 
species of origin, producer, #CAS. B) Secondary antibodies and associated procedure. 
Immunoblotting (IM), immunofluorescence (IF), and immunohistochemistry (IH).  
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2.11 Nanoparticles. 
2.11.1 Nanoparticle Construction and Drug Encapsulation: Nanoparticles were constructed 
and drug was encapsulated in Dr. Zhu lab, MCV. Five differing nanoparticle subunits were used, 
each forming their own micelle structure. 2 mg of Nanoparticle subunits were dissolved in 100 
µL of tetrahydrofuran. Drug is dissolved into 250 µL of methanol. 50 µL of drug solution is 
mixed with the nanoparticle subunit solution. The combination mixture was added into 2 mL of 
ddH2O and stirred at RT overnight to allow drug encapsulation and organic reagents to 
evaporate. Solution was centrifuged at 5,000 rpm for 5 minutes to separate the unloaded drug 
and free polymer. Supernatant was filtered with 0.45 µm filter membrane, resulting in the 
solution of micelle nanoparticle loaded with drug. (Table 2) 
 
 
 
 
 
Table 2: Nanoparticle Subunits: Five different nanoparticle micelle structures were used in this study. 
Each structure was made of one type of nanoparticle subunit. Each subunit shares the mPEG5k base. 
The displayed monomer structure subunit is repeated to form polymers of various size and attached to 
the mPEG5k base. The molecular weight (kDa) of the polymer is indicated by the subscript value. The 
weight and structure of subunit effects its uptake into the cell.       
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Chapter 3: Rationale and Results 
3.0 Rationale and Aim. 
The previous studies have found that the S1PR2/SphK2-mediated signaling pathways are linked 
to CCA cell growth. The overall goal of this study is to determine the effect of inhibiting SphK2 
on CCA cell growth. 
- Sub Aim 1: Test ABC294640 ability to inhibit CCA and CAFs.  
- Sub Aim 2: Determine the mechanical effect of ABC294640 on CCA and CAFs cells.  
- Sub Aim 3: Test nanoparticle delivery of ABC294640. 
3.1 Effect of SphK2, ABC294640, on CCA and CAF cells. 
Previous research has indicated that CCA has increased the expression of S1PR2 and its 
downstream target, SphK227,44. Inhibiting S1PR2 has proven to inhibit the progression of CCA27. 
This study's focus was determining if inhibiting SphK2 halts the progression of CCA. The 
primary SphK2 competitive inhibitor chosen for this study is ABC294640, due to its approval for 
use in clinical trials37. ABC294640 dosage assay was conducted on CCA cells, to determine if 
inhibiting SphK2 activity affects the viability of CCA cells. 
Five differing rat CCA cell lines were selected that represented the spectrum of CCA. 
BDE1 cells are non-tumorigenic immortalized cholangiocytes and act as a negative control. 
BDEsp-TDEH10 is an unmodified CCA cell line. BDEsp-TDEneu and BDEsp-TDEc are more 
aggressive forms of CCA. BDEsp-TDEneu possesses a mutation that increased the expression of 
HER2. BDEsp-TDEc has an empty vector to act as a control for BDEsp-TDEneu. To determine if 
the treatment affected CAFs cells, BDEsp-TDFE4 was included in the dosage assay.  
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The cells were plated in 96-well plates to a confluency of 60% to 80%. The individual 
plates were treated with various amounts of ABC294640, ranging from 1.0 to 25.0 µM. After 48 
hours of treatment incubation, the cell viability for each treatment dosage was measured with 
CCK-8 as described in the methods. The viability levels were plotted by the relative percentage 
of survival vs. log10 of ABC294640 dosage. A dosage curve was calculated, revealing the IC50 
for each cell line (Figure 10). The general trend of these results suggests that ABC294640 
lethality to a cell line is positively correlated with the malignancy level of the cell line; with 
BDE1, the least malignant, having the highest IC50 of 16.1 µM while BDEsp-TDEneu, the most 
malignant, had the lowest IC50 of 9.6 µM, though this is not significant. Interestingly BDEsp-
TDEH10 had an IC50 of 15.1 µM while its CAF partner, BDEsp-TDFE4, had an IC50 of 14.0 µM; 
suggesting ABC294640 can also disrupt the cancer microenvironment by inhibiting the CAF 
cells.  
3.2 Viability Measure of CCA and CAF Cells Treated with ABC294640 and/or TCA. 
The activation of S1PR2, an upstream activator of SphK2, leads to an increase in the 
growth of CCA cells28. The CBA, Taurocholic acid (TCA), is a ligand of S1PR2 and has been 
linked to the increased progression of CCA19. To determine if ABC294640 can alter the 
promoting effects of TCA on CCA, a cell viability assay was conducted. To fully represent a 
CCA tumor, both CCA cells, BDEsp-TDEH10, and CAF cells, BDEsp-TDFE4, were tested. The 
two cell types were plated in 96-well plates to a confluency of 60% to 80%. The individual wells 
were treated with TCA and/or ABC294640. The TCA treatment levels were 25.0, 50.0, and 100 
µM. The ABC294640 treatment levels were 12.5 and 25.0 µM. The TCA treatment levels of the 
two cell types were plated in 96-well plates to a confluency of 60% to 80%. The individual wells  
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Figure 10: ABC294640 Dosage Assay of Cholangiocarcinoma Cell lines. ABC294640 
dosage assay of BDE1, BDEsp-TDF
H10
, BDEsp-TDE
H10
, BDEsp-TDE
neu
, and BDEsp-TDE
neu
 
cell lines. Survival vs. Log10 of ABC294640 concentration dosage curves for varies CCA and 
CAF cell lines 48 hours after treatment. SD bars, means, IC
50
 values, and R
2
 are included. n = 
3. Calculations were done on GraphPad prism. 
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were treated with TCA and/or ABC294640. The TCA treatment levels were 25.0, 50.0, and 100 
µM. The ABC294640 treatment levels were 12.5 and 25.0 µM. The TCA treatment levels of 
50.0 and 100 µM were paired with both ABC294640 treatment levels. The singular or 
combination treatments were added to the 96-well plate After 48 hours of treatment incubation, 
the cell viability for each treatment dosage was measured with CCK-8 as described in the 
methods. The viability of the various treatment types was compared to control. 
The TCA dosage of 50.0 µM significantly (P* = 0.0471) increased the viability of 
BDEsp-TDEH10 cells, while the other TCA dosages did increased viability, but not (P > 0.05) 
significantly. All Treatments including ABC294640 had significantly (12.5 µM, *P < 0.05 and 
25.0 µM, ***P < 0.001) reduced viability. Both TCA dosages (50.0 µM and 100 µM) had 
significantly (**P < 0.01) higher viability than their TCA and ABC294640 cotreatment 
counterparts. The viability of cells treated with both ABC294640 and TCA was equivalent to 
cells treated with only ABC294640. This indicates that ABC294640 can completely counter the 
promoting effect TCA has on CCA. (Figure 11) 
 TCA dosage of 100 µM significantly (P* = 0.013) decreased the viability of BDEsp-
TDFE4 cells, while the other TCA dosages did decreased viability, but not (P > 0.05) 
significantly. All Treatments including ABC294640 had significantly (12.5 µM, **P < 0.01 and 
25.0 µM, ***P < 0.001) reduced viability. TCA dosages (50.0 µM and 100 µM) had 
significantly (*P < 0.05) higher viability than their TCA and ABC294640 cotreatment 
counterparts. The viability of cells treated with both ABC294640 and TCA was equivalent to 
ABC294640 treatment. This data suggests that TCA at high dosages is toxic to BDEsp-TDFE4 
and that ABC294640 nullifies this toxicity while remaining toxic itself. (Figure 12) 
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Figure 11: BDEsp-TDEH10 Cells Viability Measure with Various Levels of TCA and/or 
ABC294640. Cells were plated in 96-well plate, 4,000 per well in 1.0% FBS medium and 
incubated overnight.  Treatment was added and incubated for 48 hours, followed by viability 
measure with CCK-8. Symbol above bars indicate significant compared to control. n = 3 and 
values are mean ± SEM. 50 µM TCA significantly (*P = 0.0471) increased viability. 
ABC294640 reduced cell viability (12.5 µM, *P < 0.05 and 25.0 µM, ***P < 0.001).  TCA 
with ABC294640 were significantly different from their only TCA counterparts (**P < 
0.01). 
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Figure 12: BDEsp-TDFE4 Cells Viability Measure with Various Levels of TCA and/or 
ABC294640. Cells were plated in 96-well plate, 4,000 per well in 1.0% FBS medium and 
incubated overnight.  Treatment was added and incubated for 48 hours, followed by 
viability measure with CCK-8. Symbol above bars indicate significant compared to 
control. n = 3 and values are mean ± SEM. 100 µM TCA significantly (*P = 0.013) 
decreased viability. ABC294640 treatments significantly reduced viability (12.5 µM, **P 
< 0.01 and 25.0 µM, ***P < 0.001. 
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3.3 Effect of ABC294640 on Taurocholic Acid-induced Formation of “Duct-Like” 
Structure in a 3-D Organotypic Culture Model of Rat CCA Cells.  
The dosage assay indicated that ABC294640 could disrupt the CCA and CAFs cells in 
tumors. To determine if ABC294640 could disrupt and inhibit tumor growth, a 3-D Organotypic 
treatment was performed. The 3-D organotypic culture is a combination of CCA, BDEsp-
TDEH10, and CAFs, BDEsp-TDFE4, cells are suspended in collagen, which forms “duct-like" 
structures. The creation of this culture has previously been described43. The cultures were treated 
for 8 days with TCA (100 µM) and/or ABC294640 (10 µM). After the treatment period, the 
cultures were fixed, sectioned, and stained with H&E (Figure 13A). The sections were imaged at 
10x magnification and the ducts were measured with ImageJ “Analyze Particle” function. The 
average size (µm2) of the “duct-like” structures were recorded. The TCA (100 µM) treatment 
(**P=0.0072) increased the size of the “duct-like” structures. The ABC294640 (10 µM) 
treatment significantly (****P < 0.0001) decreased the size of the “duct-like” structures. TCA 
and ABC294640 combination treatment had larger (*P = 0.0281) “duct-like” structure then the 
ABC294640 treatment, while still having significantly smaller (****P < 0.0001) structures then 
the TCA treatment group (Figure 13B). The count of the “duct-like” structures was recorded. 
The TCA (100 µM) treatment (**P = 0.009) increased the count of the “duct-like” structures. 
The ABC294640 (10 µM) treatment significantly (****P < 0.0001) decreased the count of the 
“duct-like” structures. TCA and ABC294640 combination treatment had fewer (****P < 0.0001) 
structures then both the control and TCA treatment groups. (Figure 13C). The TCA treatment 
was able to increase the size and amount of “duct-like” structures, indicating that activation of 
the S1PR2/SphK2 pathway does promote the growth of the simulated tumors. The inhibition of 
SphK2 by ABC294640 decreased the size and amount of the “duct-like”, as  
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Figure 13: 3-D Organotypic Co-Culture. TCA and ABC294640 Treatment of BDEsp-TDE
H10
 and 
BDEsp-TDF
E4
 Cells 3-D Organotypic Co-culture. Rat BDEsp-TDE
H10
 and BDEsp-TDF
E4
 co-culture 
were solidified together in rat tail type-1-collagen gel disk. The co-culture disk was incubated for 8 
days with 100 µM TCA and/or 10 µM ABC294640 treatments. The co-culture was fixed and sectioned. 
The section was stained with H&E. Images were taken of the “duct-like” structures in each sample. 
Duct size and count was quantified with ImageJ. Symbol above bars indicate significant compared to 
control. Line indicates mean. n = 9. (A) Representative image of H&E stained spheroid/“duct-like” 
structures for each treatment. (B) The average size (µm2) of “duct-like” structures per image. TCA 
treatment did (**P=0.0072) increase the size of “duct-like” structures. Both groups treated with 
ABC294640 had significantly (****P < 0.0001) reduced size, while the combination treated group 
had larger (*P = 0.0281) structures compared to the ABC294640 treatment group. TCA treatment and 
TCA with ABC294640 were significantly (****P < 0.0001) different. (C) Count of “duct-like” 
structure per image. 100 µM TCA had a significant ((**P = 0.009) increased count. Both groups treated 
with ABC294640 had significantly (****P < 0.0001) reduced count and had equivalent counts. TCA 
treatment and TCA with ABC294640 were significantly (****P < 0.0001) different. 
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expected. The ABC294640 and TCA combination treatment had equivalent “duct-like” structure 
count compared to ABC294640 treatment, which indicates that ABC294640 treatment could be 
halting the tumor's ability to metastasize and migrate to another portion of the culture. These 
results agree with a study that conducted the same experiment with S1PR2 inhibitor treatment28. 
3.4 Cell Migration Assay.  
CCA tumor’s metastasis and infiltration capability are largely dependent on the CAFs 
cells, which detaches from the surrounding tissue allowing the tumor to metastasize and are at 
the front of tumor migration. To determine if ABC294640 can inhibit CAFs role in cancer 
metastasis, a migration assay was conducted. The protocol of the migration assay is described in  
the methods. The cells were treated with TCA (100 µM) and/or ABC294640 (12.5 or 25 µM). 
The images were taken immediately before treatment and 36 hours after treatment. TCA (100 
µM) increased (****P < 0.0001) the migration rate of BDEsp-TDFE4. ABC294640 decreased 
(**P < 0.002) the migration rate of BDEsp-TDFE4 cells. Interestingly, 12.5 µM ABC294640 
treatment with and without TCA were equivalent. This could indicate that even at a low dosage, 
ABC294640 can block the effects of TCA. The 25 µM ABC294640 dosage was very effective 
(****P < 0.0001) at inhibiting migration, though TCA was able to counter this slightly (**P = 
0.0026). (Figure 14) 
 The same migration assay was conducted with BDEsp-TDEH10 cells with the same 
procedure. The final images were taken at 24 hours after treatment, due to BDEsp-TDEH10 higher 
migration rate. The TCA treatment increased (*P = 0.0217) the migration rate of the BDEsp-
TDEH10 cells, but not as significant (****P < 0.0001) as the BDEsp-TDFE4 cells. 12.5 µM 
ABC294640 treatment reduced (**P = 0.001) the migration rate of BDEsp-TDEH10. The 25 µM 
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ABC294640 treatment was able to significantly reduce the migration rate (**P < 0.005) of 
BDEsp-TDEH10. (Figure 15)  
The migration rate is increased by TCA (100 µM) treatment and decreased by 
ABC294640 treatment in both BDEsp-TDEH10 and BDEsp-TDFE4 cell lines. The low dosage of 
ABC294640 (12.5 µM) can counter TCA treatment. (Figures 14 and 15)  
3.5 Nanoparticle Delivery of SphK2 Inhibitor. 
Nanoparticle constructs can improve the transport of SphK2 inhibitor molecules to CCA 
cells, by removing the difficulty the hydrophobic molecules have moving through the 
plasma/lymph. We partnered with Dr. Zhu lab to develop and test nanoparticle's ability to deliver 
SphK2 inhibitors to CCA, BDEsp-TDEH10, cells and their associated CAFs, BDEsp-TDFE4. Five 
nanoparticle constructs were developed and implanted with the inhibitors, ABC294640 and 
K145. 
The two cell types were plated in 96-well plates to a confluency of 60% to 80%. The 
individual wells were treated with SphK2 inhibitor (ABC294640 and K145) within or without 
the nanoparticle construct. The ABC294640 treatment dosages were 12.5 and 25 µM. The K145 
treatment dosages were 5.0 µM and 10 µM. These dosages seem to be less effective than 
previous dosage assay, possibly due to the nanoparticle encapsulation process degrading the 
drug. The free drug went through the same process and still acts as an effective positive control.  
Treatments were added to corresponding wells of 96-well plate. After 48 hours of treatment 
incubation, the cell viability was measured with CCK-8 as described in the methods. The final 
viability of each treatment type was compared with control. 
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Figure 14: BDEsp-TDF
E4
 Migration Assay with TCA (100 µM) and/or ABC294640 (12.5 
and 25 µM) Treatments. Cells were plated to 70% - 80% confluency in 6-well plate with 10% 
FBS medium. A wound was scratched down the middle of the plate and the medium was placed 
with 1.0% FBS medium. Images were taken at 4x magnification. Initial images were taken and 
treatment was added. Final image was taken at 24 hours. (A) Initial and final images of scratch 
assay of various treatments. Experiment was replicated 3 times and each well had imaging 3 
spots, n = 9. Values are mean ± SEM. (B) Distant of migration normalized to control. TCA 
increased (****P < 0.0001) migration rate. 12.5 µM ABC294640 with TCA treatment did have 
significant (*P = 0.0481) decrease in migration and 12.5 µM ABC294640 treatment did see a 
decrease (**P = 0.002) in migration. Both treatments with 25 µM ABC294640 had significant 
(**P < 0.0001) decrease in migration. Both TCA and 12.5 µM ABC294640 combination 
treatments were equivalent to their 12.5 µM ABC294640 treatment counterpart, while TCA and 
25 µM ABC294640 treatment had increased (**P = 0.0026) migration compared to 25 µM 
ABC294640.  
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Figure 15: BDEsp-TDE
H10 
 Migration Assay with TCA (100 µM) and/or ABC294640 (12.5 
and 25 µM) Treatments. Cells were plated to 70% -  80% confluency in 6-well plate with 10% 
FBS medium. A wound was scratched down the middle of the plate and the medium was placed 
with 01% FBS medium. Images were taken at 4x magnification. Initial images were taken and 
treatment was added. Final image was taken at 36 hours. (A) Initial and final images of scratch 
assay of various treatments. (B) Distant of migration normalized to control. Experiment was 
replicated 3 times and each well had imaging 3 spots, n = 9. TCA increased (*P = 0.0217) migration 
rate. 12.5 µM ABC294640 with TCA treatment did not have significant decrease in migration, 
while 12.5 µM ABC294640 treatment did see a decrease (**P = 0.001) in migration. Both 
treatments with 25 µM ABC294640 had significant (**P < 0.005) decrease in migration. Both TCA 
and ABC294640 combination treatments were equivalent to their ABC294640 treatment 
counterpart. 
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Figure 16: Nanoparticle Delivery of SphK2 Inhibitors Viability Assay. The treatments were 
delivered in free form or in one of the 5 design nanoparticle constructs. The ABC294640 treatment 
dosages were 12.5 µM and 25 µM. The K145 treatment dosages were 5.0 µM and 10 µM. n = 3 and 
values are mean ± SEM. A) The viability measure of BDEsp-TDE
H10
. B) The viability measure in 
BDEsp-TDF
E4
. 
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In the BDEsp-TDEH10 cells, nanoparticle type 5 was the most effective in both drug types. 
In BDEsp-TDFE4, none of the nanoparticles were effective. More research and development need 
to be conducted. (Figure 16) 
3.6 Effect of SphK2 inhibitor on Histone Acetylation in rat CCA and CAFs cells. 
As described before (Figure 6), TCA can induce acetylation via the S1PR2/SphK2 
pathway. To determine if this pathway is maintained in CCA (BDEsp-TDEH10) and CAFs 
(BDEsp-TDFE4), cells were treated with TCA, and acetylated histone levels were measured with 
immunoblotting. Cells were plated to 70% to 80% confluency. The cells medium was refreshed 
with 1.0% FBS medium and allowed to incubate for 1 hour. The TCA dosages of 0, 50, 100, and 
200 µM were added to the plates and allowed to incubate for 4 hours in a cell incubator. Once 
incubation completed, the nuclear protein was extracted. Immunoblotting for H4K5, H2BK12, 
H3K9, and H3 as an internal standard was performed as described in the methods. In BDEsp-
TDEH10 the TCA treatments of 50 µM (*P < 0.05 ) and 100 µM (**P < 0.01) increased 
acetylation consistently across the various histones. In BDEsp-TDFE4 the TCA treatments did not 
increase histone acetylation. The TCA (200 µM) treatment did decrease (**P < 0.01) the 
acetylation of H3K9. This data suggests that the BDEsp-TDEH10 cells are being affected by TCA 
treatment via the S1PR2/SphK2 pathway, while the BDEsp-TDFE4 is being affected in a 
different way or on a different time scale (Figure 17). TCA treatment is inducing histone 
acetylation in BDEsp-TDEH10 cells, ABC294640 could possibly affect this increased acetylation. 
The same procedure for preparing and treating the cells was followed, except that BDEsp-
TDEH10 cells were treated with TCA (100 µM) and/or ABC294640 (25 µM). 4 hours after 
treatment, the nuclear protein was extracted. Immunoblotting for H4K5, H3K9, and H3 as an 
internal standard was performed as described in the methods. the nuclear protein was extracted. 
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Figure 17: TCA Effect on Histone Acetylation. Protein was collected from BDEsp-TDE
H10 
and 
BDEsp-TDF
E4
 cell lines treated with various TCA levels for 4 hours, followed by nuclear protein 
extraction as described in the methods and stored at -80 °C. Protein levels of H4K5, H2KB12, 
H3K9, and H3 (standard) were determined by immunoblotting analysis. (A) Representative 
images of immunoblotting of cell treated with various levels of TCA treatments. Statistical: n = 
3 and values are mean ± SEM. Student t-test was used to determine if protein levels were 
significant between treatments. (B)  Quantification of average protein levels for the four 
treatments. In BDEsp-TDE
H10 
the 50 µM (*P < 0.05) and 100 µM (**P < 0.01) of TCA treatment 
increased acetylation constantly across all type of histones. In BDEsp-TDF
E4
 the TCA treatments 
did not increase histone acetylation. The 200 µM treatment did decrease (**P < 0.01) the 
acetylation of H3K9. 
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Immunoblotting for H4K5, H3K9, and H3 as an internal standard was performed as described in 
the methods. H2KB12 was not repeated due to a lack of antibodies. The treatments changed the 
acetylation levels of histones in BDEsp-TDEH10. For H4K5 and H3K9, TCA (100 µM) increased 
(*P < 0.05) acetylation, TCA (100 µM) with ABC294640 (25 µM) decreased (*P < 0.05) 
acetylation, and ABC294640 (25 µM) treatment’s histone acetylation level was equivalent to the 
control. The difference of acetylation is significant (**P < 0.01) between TCA (100 µM) with or 
without ABC294640 (25 µM). There was no significant difference between ABC294640 (25 
µM) treatments with or without TCA (100 µM). ABC294640 is halting the acetylation induced 
by TCA treatment, yet doesn’t reliably decrease acetylation by itself. This makes ABC294640 a 
more promising CCA treatment if the drug specifically targets cells with highly active SphK2. 
(Figure 17)    
3.7 Hematoxylin and Eosin Staining of Human Samples. 
To determine if the CCA patients had liver maladies, samples were assessed by a 
histologist. The sample slides were stained with hematoxylin and eosin (H&E) and sent for 
evaluation. The CCA patient samples had signs of various liver malformations and damage. This 
includes steatosis, Cirrhosis, fibrosis, mild cholestasis, ductal proliferation, and polymorphous 
infiltrate. These results confirm that CCA patients’ livers were undergoing stress associated with 
CCA (Figure 19). 
3.8 TROMA-III (CK-19) Staining of Human Samples. 
CK-19 is a marker for fibrosis and for cancer infiltration. CCA patient’s samples were 
probed for CK-19, followed by immunohistochemistry staining. CCA patients had a slight  
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Figure 18: Effect of TCA and/or ABC294640 Treatment of Histone Acetylation in CCA Cells.   
Protein was collected from BDEsp-TDE
H10
 cell lines treated with various TCA (100 µM) and/or 
ABC294640 (25 µM) for 4 hours, followed by nuclear protein extraction as described in the methods 
and stored at -80 °C. Protein levels of H4K5, H2KB12, H3K9, and H3 (standard) were determined 
by immunoblotting analysis. (A) Representative images of immunoblotting of cell of TCA and/or 
ABC294640 treatments. (B)  Quantification of average protein levels for the four treatments. 
Statistical significance: n = 3 and values are mean ± SEM. Student t-test was used to determine if 
protein levels were significant between treatments. For both H4K5 and H3K9, TCA (100 µM) has 
increased (H4K5: **P = 0.0035, H3K9: *P = 0.0358) acetylation, TCA (100 µM) with ABC294640 
(25 µM) has decreased (H4K5: *P = 0.0373, H3K9: **P = 0.0225) acetylation, and ABC294640 (25 
µM) doesn’t have a change in acetylation. The difference of acetylation is significant (H4K5: **P = 
0.0019, H3K9: **P = 0.0085) between TCA (100 µM) with or without ABC294640 (25 µM). There 
was no significant difference between ABC294640 (25 µM) treatments with or without TCA (100 
µM).  
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Figure 19: H&E staining of liver sections originated from CCA patients or patients that 
passed away due to brain trauma (Controls). Samples were stained with H&E and 
analyzed by a histologist. Images of 4x and 10x magnification accompanied by histologist 
diagnosis of sample. CCA patient samples had various signs of liver disease that is linked to 
CCA. These includes steatosis, Cirrhosis, fibrosis, mild cholestasis, ductal proliferation, and 
polymorphous infiltrate.  
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Figure 20: Immunohistochemistry TROMA-III (CK-19) staining of liver sections originated 
from CCA patients or patients that passed away due to brain trauma (Controls). TROMA-III 
(CK-19) is a marker for fibrosis. Samples were probed with TROMA-III (CK-19) followed by 
immunohistochemistry staining. CCA patient liver samples had slightly increased levels of CK-19. 
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increase in CK-19 expression compared to control, but not significantly. This collaborates with 
the histologist's conclusion on the H&E stained samples (Figure 20).    
3.9 Quantifying Protein Expression of Human Liver Samples. 
Protein levels of S1PR2, SphK2, and SphK1 in CCA patients were measured. Total 
protein lysate was collected from CCA patients and control patients (head trauma) liver samples. 
Three portions from different parts of the liver were collected for each sample. The protein 
samples were collected and immunoblot as described in the methods. The CCA patient samples 
have increased levels of S1PR2 (**P = 0.0033) compared to the control. This paired with the 
increased (*P = 0.0497) levels of SphK2 indicates the S1PR2/SphK2 pathway is upregulated in 
CCA patient liver. A slight increase in SphK1 was detected which can contribute to the 
activation of the S1PR2 via S1P.  
3.10 Sphingosine Kinase 2 and Sphingosine-1-Phosphate Receptor 2 Immunofluorescence 
Histochemistry of Human Samples. 
To support the protein quantification results of the human samples, immunofluorescence 
histochemistry of SphK2 and S1PR2 was conducted. The sample slides were prepared as 
described in the methods and probed for SphK2 and S1PR2. The samples tested positive for both 
probed proteins and it appears that the CCA samples possessed higher levels of both proteins 
(Figure 22).  
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Figure 21: Immunoblotting of Human Samples. Protein was collected from human liver 
samples the originated from CCA patients or patients that passed away due to brain trauma 
(Controls). 50 mg of liver tissue was homogenized in 1.0 mL of total protein lysis buffer and 
stored at -80 °C. Protein levels of SphK2, S1PR2, SphK1, and Actin (standard) were 
determined by immunoblotting analysis. Statists: 3 liver section from each 8 samples from 
each group, n = 24. Values are mean ± SEM. Student t-test was used to determine if protein 
levels were significant between groups. (A) Representative images of immunoblotting for 
individual patient samples. (B)  Quantification of average protein levels for the two groups. 
S1PR2 (**P = 0.0033) was significant, SphK1 (P = 0. 5697) was insignificant, and SphK2 
(*P = 0.0497) was significant.  
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Figure 22: Immunofluorescence Imaging of Patient Samples. Immunofluorescence 
probing of liver sections originated from CCA patients or patients that passed away due to 
brain trauma (Controls). Samples were probed for SphK2 or S1PR2, followed by DAPI 
staining. Images were taken with a fluorescence confocal microscope. IgG negative control 
Included. It appears that the CCA samples contained higher levels of SphK2 and S1PR2. 
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Chapter 4: Discussion 
Cholangiocarcinoma (CCA) diagnosis rate has been increasing, especially outside the 
regions it is traditionally found1. 20% of CCA cases are identified at the early stage of the 
disease, this allows for early treatment giving the patient a 30% to surviving 5-year past 
diagnosis. Patients diagnosed at the late stages of CCA have ~2% of survival over the same time 
period, even with treatment2, 43. The increasing rate of CCA in the global population and the 
ineffectiveness of treatment at the early and late stages of the disease have created a growing 
need for novel CCA treatments. Current research indicates that the activation of sphingosine-1-
phosphate-receptor-2 (S1PR2) promotes the progression of CCA, possibly through sphingosine 
kinase 2 (SphK2)27. S1PR2 activation leads to the activation of SphK2 in the nucleus, where 
SphK2 indirectly deactivates HDAC1/2 leading to increased histone acetylation and alteration of 
gene expression26. This epigenetic effect could be the reason for SphK2 activity being associated 
with cancer neoplastic transformation, tumorigenesis, migration, proliferation, metastasis, 
metabolism, drug resistance, and overall cancer progression27, 44 - 46. SphK2 links to cancer 
progression make it a prime target for treatment.  
Recently ABC294640, an SphK2 competitive inhibitor, has been approved for the 
clinical trial at 250 mg oral daily dosage (~ 7 µM)36,47. In phase I clinical study with a panel of 
patients with different cancers, a patient suffering from metastatic CCA was given a daily 
regimen of 250 mg ABC294640 treatment. This CCA patient had the best outcome out of the 
study, which is encouraging and anecdotal47. ABC294640 ability to treat CCA is not well 
understood. This study examined if ABC294640 can halt or reverse the progression of CCA and 
the underlining mechanism of this effect.  
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This study employed various rat CCA, CAF, and cholangiocytes cell lines. To ensure that 
the ABC294640 treatment could effectively inhibit CCA progression at a reasonable dosage, a 
dosage assay was done on the panel of CCA cell types. The cells least affected by the treatment 
were the healthy cholangiocytes, BDE1, with an IC50 of 16.1 µM, which suggests that 
ABC294640 treatment is less toxic to healthy cells compared to the cancer cell lines, though this 
is speculative. The CCA cell lines BDEsp-TDEH10, BDEsp-TDEC, and BDEsp-TDEneu had IC50 
of 15.1 µM, 10.2 µM, and 9.6 µM respectively (Figure 10). A recent study on human 
intrahepatic CCA cell lines found ABC294640 treatment reduced the viability in the human 
CCA cell lines47, indicating ABC294640 can be an effective treatment for targeting patient’s 
CCA cells. Interestingly, cancer-associated myofibroblasts (CAFs) cell line, BDEsp-TDFE4, had 
a similar IC50, 14 µM, to the CCA cell lines (Figure 10). CAFs are important for the 
development of the cancer microenvironment as the CCA cell themselves29, thus ABC294640 is 
capable of inhibiting CAFs bolster its use as a CCA treatment. Since all the CCA cell lines had 
similar responses, we decided to focus on BDEsp-TDEH10 representing CCA and BDEsp-TDFE4 
representing CAFs. 
S1PR2 activation of SphK2 is necessary for SphK2 rule in CCA progression27. To 
determine if the S1PR2 pathway was intact and if the pathway could be blocked by ABC294640, 
a viability assay of BDEsp-TDFE4 and BDEsp-TDEH10 was conducted. The CBA ligand, 
taurocholic acid (TCA), was used to activate S1PR2 pathway. Surprisingly the TCA (100 µM) 
treatment reduced the viability of CAFs, BDEsp-TDFE4, but the ABC294640 treatments 
continued to reduce the cell viability with or without the presence of TCA (Figure 12). More 
predictively, the CCA cells, BDEsp-TDEH10, viability was increased be the TCA treatments. The 
ABC294640 treatments were able to completely counter the effects of TCA, with cells treated 
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with ABC294640 and TCA having equivalent viability to cells treated with only ABC294640 
(Figure 11). This suggests that the ABC294640 can completely block the TCA ability, via 
S1PR2/SphK2 pathway, to increase cell viability.  
After determining ABC294640 can effectively inhibit the CCA and CAFs that compose 
CCA tumors, treatment of the simulated tumor was conducted. The 3-D organotypic culture was 
made with BDEsp-TDFE4 and BDEsp-TDEH10, which together form “duct-like” structures that 
are a simulation of CCA tumors. The cultures were treated with TCA to promote and/or 
ABC294640 to inhibit the progression of the simulated CCA tumors. TCA treatment increased 
the size and number of the “duct-like” structures, indicating that promoting the S1PR2 pathway 
quickens the growth and possibly metastasis of the CCA. ABC294640 treatment did the opposite 
even in the cotreatment with TCA (Figure 13). This indicates that ABC294640 can stop tumor 
growth and metastasis even when the activity of S1PR2 and SphK2 is increased. This outcome is 
supported by a study that had a similar result with S1PR2 inhibitor instead of an SphK2 
inhibitor27.     
To conform ABC294640 ability to halt CCA migration/metastasis, a migration assay was 
conducted with BDEsp-TDFE4 and BDEsp-TDEH10. The migration assay was done with TCA 
and/or ABC294640 treatments (Figures 14 and 15). In both cell lines, TCA significantly 
increased and ABC294640 decreased migration, supporting ABC294640 ability to inhibit CCA 
metastasis. ABC294640 ability to inhibit CAFs, BDEsp-TDFE4, migration rate is important, due 
to CAFs rule of spearheading migration for the CCA tumors29.  
It was previously discussed that SphK2 indirectly increases the level of histone 
acetylation26. To determine if this pathway was present in BDEsp-TDFE4 and BDEsp-TDEH10 
cell lines, the cells were treated with various levels of TCA and then the histone acetylation 
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levels were measured with immunoblotting. In CCA, BDEsp-TDEH10, the 50 and 100 µM TCA 
treatments increased histone acetylation. The CAFs, BDEsp-TDFE4, histone acetylation 
decreased after TCA treatment, but this was only significant with H3K9 at 200 µM dosage 
(Figure 17). The S1PR2/SphK2/HDAC1/2 pathway is functional in the BDEsp-TDEH10 cell line, 
allowing it to be a modal to determine if ABC294640 treatment could affect histone acetylation. 
The same experiment was repeated on BDEsp-TDEH10 with TCA (100 µM) and/or ABC294640 
(25 µM) treatments. The TCA treatment maintained its ability to increase histone acetylation. 
More interestingly is ABC294640 didn’t reliably decrease acetylation by itself, but when paired 
with TCA the histone acetylation levels significantly dropped (Figure 18). This can indicate that 
ABC294640's ability to decrease histone acetylation is only effective when SphK2 activity is 
increased by S1PR2 and not when Sphk2 is at basal activity levels.  
The ABC294640 seems to be effective at halting the S1PR2/SphK2 pathway in the CCA 
cell model. More evidence needs to be present to support ABC294640 as a possible clinical 
treatment for CCA. To confirm if ABC294640 target pathway was significantly present in 
patients diagnosed with CCA, SphK2 and S1PR2 quantification was conducted on patient liver 
samples. The liver disease state of the patients was confirmed with H&E and CK-19 staining of 
the sample slides, which both showed the patients had various signs of liver disease (Figures 19 
and 20). The SphK2 and S1PR2 levels were measured with immunoblotting and 
immunofluorescence, both methods conforming an increase in SphK2 and S1PR2 in CCA 
patients compared to controls (Figure 21 and 22). The increased expression of SphK2 and 
S1PR2 in CCA patient samples supports the singular phase I clinical study that indicated 
ABC294640 as an effective treatment for CCA47.  
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Based on this study, ABC294640 shows great promise as a CCA treatment for the 
following reasons. The drug has higher toxicity to CCA cell lines compared to the healthy 
cholangiocyte cell line. The inhibiting effects were also effective on CAFs, which are important 
for CCA progression. The treatment stopped the metastasis and growth of tumors, even in the 
presence of the CCA promoter, TCA. The drug's mechanical effect of stopping histone 
acetylation may only affect cells with highly active SphK2, which makes the drug more specific 
toward CCA cells. Finally, the target pathway is highly expressed in human CCA samples.  
An unanswered question in this study is how ABC294640 is inhibiting CAFs. Neither 
TCA or ABC294640 treatment affects CAF cells as expected. In fact, TCA seems to increase the 
CAFs migration rate, while decreasing histone acetylation and viability. With ABC294640 
functionally being the opposite of TCA, you would expect that ABC294640 would at least not 
affect CAFs cell viability, but it decreases it. This may be due to ABC294640 inhibiting SphK2 
in another portion of the cell, such as the cytoplasm or mitochondria49,50. This needs to be further 
studied. 
In conclusion, ABC294640 seems to effectively decrease CCA cells’ migration and 
viability by stopping SphK2 from increase histone acetylation and ABC294640 is inhibiting 
CAFs by some unidentified mechanism. The drug is also able to halt growth and metastasis of 
CCA tumors. CCA reliance on increased SphK2 activity is supported by SphK2 and S1PR2 
levels of the CCA patient samples. More research should be done to determine how ABC294640 
can be safely used as a clinical treatment for CCA.             
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